New Gilead non-Peg non-Riba study starting between 10/2013 - 11/2013 for Genotype 1's & 4's at NIH.
mehru said
Sep 12, 2013
Thanks Matt for outlining the details, my head is spinning over this opportunity. The RN at NIH said I would probably qualify, but the screening is 5 hours of testing and my history is so borderline to their exclusion list. Then I'd have to commit to 8 an week study with additional housing expense during tx if I were approved. Well, they have my medical history paperwork (33 pages) sent to them electronically and just yesterday they emailed me saying they would get back if they needed additional info from me. It would be great if they had this study in other parts of the country as well. Although NIH seems very particular doing everything at their own facility.
Matt Chris said
Sep 12, 2013
Hey Mehru
Thanks for posting this trial info. I checked it out and the study will have both cirrhotics and non-Cirrhotics in the study. They will also have treatment experineced and naive in its nine different arms. Gilead will be testing it's Sofosbuvir combined with it's other DAA's
Here is there outlined Objectives: - To see whether GS-7977 with GS-5885 alone or in combination with either GS-9669 or 9451 can be used to treat HCV infection
Looks like they are trying to find the best combo for mostly Geno 1 , they are having one Geno 4 group as well.
So far they have listed only Maryland and the D.C. Area is the sites in the US
This would be a good study to try to get into, but they have a long list of exclusion criteria which are clearly listed on the ClinicalTrials.Gov
Matt
mehru said
Sep 12, 2013
You have to be in Washington, DC area during tx. I am considering doing this one but have to look in to cost of temporary housing. Also, I would have to be approved.
Combination Therapy for Chronic Hepatitis C Infection
This study is currently recruiting participants.
Verified December 2012 by National Institutes of Health Clinical Center (CC)
- GS-7977, GS-5885, GS-9669, and GS-9451 are new drugs for treating hepatitis C virus (HCV) infection. GS-7977 may help treat the infection when used with other treatments like interferon therapy. GS-5885, and GS-9669, and GS-9451 also lower the amount ofHCV in the body. Researchers want to see whether GS-7977 can be combined with any of the other three drugs to treat HCV infection. Some participants will take GS-7977 and GS-5885. Others will take GS-7977, GS-5885 and GS-9669 or GS-7977, GS-5885 and GS-9451.
Objectives:
- To see whether GS-7977 with GS-5885 alone or in combination with either GS-9669 or 9451 can be used to treat HCV infection.
Thanks Matt for outlining the details, my head is spinning over this opportunity. The RN at NIH said I would probably qualify, but the screening is 5 hours of testing and my history is so borderline to their exclusion list. Then I'd have to commit to 8 an week study with additional housing expense during tx if I were approved. Well, they have my medical history paperwork (33 pages) sent to them electronically and just yesterday they emailed me saying they would get back if they needed additional info from me. It would be great if they had this study in other parts of the country as well. Although NIH seems very particular doing everything at their own facility.
Hey Mehru
Thanks for posting this trial info. I checked it out and the study will have both cirrhotics and non-Cirrhotics in the study. They will also have treatment experineced and naive in its nine different arms. Gilead will be testing it's Sofosbuvir combined with it's other DAA's
Here is there outlined Objectives: - To see whether GS-7977 with GS-5885 alone or in combination with either GS-9669 or 9451 can be used to treat HCV infection
GS-7977 = Sofosbuvir - Nucleoside Polymerase Inhibitor
GS-5885 = Ledipasvir - NS5A Inhibitor
GS- 9669 = Non-Nucleoside Polymerase
GS-9451 = Protease Inhibitor
Looks like they are trying to find the best combo for mostly Geno 1 , they are having one Geno 4 group as well.
So far they have listed only Maryland and the D.C. Area is the sites in the US
This would be a good study to try to get into, but they have a long list of exclusion criteria which are clearly listed on the ClinicalTrials.Gov
Matt
You have to be in Washington, DC area during tx. I am considering doing this one but have to look in to cost of temporary housing. Also, I would have to be approved.
Combination Therapy for Chronic Hepatitis C Infection
Background:
- GS-7977, GS-5885, GS-9669, and GS-9451 are new drugs for treating hepatitis C virus (HCV) infection. GS-7977 may help treat the infection when used with other treatments like interferon therapy. GS-5885, and GS-9669, and GS-9451 also lower the amount ofHCV in the body. Researchers want to see whether GS-7977 can be combined with any of the other three drugs to treat HCV infection. Some participants will take GS-7977 and GS-5885. Others will take GS-7977, GS-5885 and GS-9669 or GS-7977, GS-5885 and GS-9451.
Objectives:
- To see whether GS-7977 with GS-5885 alone or in combination with either GS-9669 or 9451 can be used to treat HCV infection.